Background. BK virus (BKV) has been implicated as a cause of nephritis and graft loss in 2%-9% of kidney transplant recipients, but the prevalence among recipients of other solid organ transplants (SOTs) has not been well established. Our objective was to determine the prevalence of BKV infection for all types of SOT recipients at our medical center.
The human polyomavirus is a ubiquitous, small, nonenveloped, double-stranded DNA virus of which 2 species have been described as potentially pathogenic in humans: JC virus (JCV) and BK virus (BKV). BKV has been implicated as a cause of nephritis and graft loss that may affect 1%-10% of recipients of kidney transplants [1] .
The role of BK virus in recipients of nonrenal solid organ transplants (SOTs) has not been determined, and only anecdotal case reports have been published to date [2] [3] [4] [5] [6] . We performed a prospective study to try to determine the prevalence of BKV replication among re-cipients of liver, heart, or kidney transplants at our medical center (Hospital General Universitario "Gregorio Marañó n," Madrid, Spain) and the relationship between BKV replication and renal function.
MATERIALS AND METHODS
We performed a prospective prevalence study. Transplantation teams were asked to submit paired urine and plasma samples from ∼50 consecutive adult recipients of SOTs who presented to the hospital (for reasons including external consultation) between 1 July 2003 and 28 February 2004. No preliminary screening was used to allow or prevent patient enrollment into the study, and all samples that arrived at the microbiology laboratory during the study period were processed. Data regarding type and date of transplantation, immunosuppressive agents received, and renal function were collected. Microscopic hematuria was defined as the presence of у3 RBCs per high-power field in at least 2 specimens of urinary sediments.
DNA extraction. Viral DNA from clinical samples was extracted with a thiocyanate-based method in which 50 mL of clinical specimen was mixed with 200 mL of lysis buffer comprising 160 mL of 5 M guanidine thiocyanate, 5 mL of 1 M sodium citrate (pH 7.0), 0.2 mL of 1 M dithiotreitol, 33.3 mL of 3% w/v sarcosyl, 1 mL of 20 mg/mL glycogen, and 0.5 mL of distilled water [7] . After incubation of this mixture for 10 min at room temperature, 250 mL of isopropanol/ethanol was added to each tube, and the samples were centrifuged for 10 min at 13,000 g. The supernatants were discarded, and the pellets were washed with 500 mL of 70% v/v ethanol. After a second centrifugation step, the ethanol was discarded, and the pellets were dissolved in 10 mL of sterile double-distilled water. DNA extracts were stored at Ϫ70ЊC until required for PCR. Amplification of BKV by nested PCR. Clinical specimens were screened for BKV DNA by using a qualitative, multiplex nested PCR for JCV, BKV, and simian virus 40 polyomaviruses [8, 9] , which amplified a specific region of the T large antigen, common to BKV, JCV, and simian virus 40. The first PCR run was generic for detection of polyomaviruses, and the second PCR run was specific for detection of BKV. PCR runs always included a plasmid as an internal control to assure detection of inhibitions. For the first PCR run, 10 mL of purified DNA was used, and 1 mL of sample from this first PCR was used as a template for the second nested reaction. Final reaction volume was always 50 mL.
Each assay included distilled water as a negative control and 100 copies of plasmid pBRV33-1 containing BKV strains as a positive control (Centro Nacional de Microbiología, Madrid). Ten clinical samples were amplified in each assay. Positive results for clinical specimens were confirmed by testing a second fresh aliquot.
To avoid false-positive PCR results due to carry-over contamination, aliquoting of clinical specimens, preparation of reagents, DNA extraction, first round amplification, and nested PCR were performed in safety cabinets located in separate laboratories. Analytical sensitivity of the procedure. Before testing the clinical samples, the sensitivity of the complete procedure was calculated by amplifying serial dilutions of plasmid in 50 mL of distilled water. Plasmid was linearized, and a stock preparation of each mixture at a concentration of copies/mL 8 2 ϫ 10 was diluted 10-fold to a concentration of copies/mL. To 2 2 ϫ 10 obtain a weak positive control (i.e., a sensitivity control), samples of plasmid containing BKV were mixed and concentrations adjusted so that 100 copies of BKV was added to each reaction tube. Conditions for extraction and amplification were the same as for the clinical samples, and all dilutions were assayed in triplicate. All experiments were conducted with positive and negative controls to exclude false-positive and false-negative results.
Statistical analysis. Quantitative variables are presented as mean values (‫ע‬SD) or median values (range) for continuous, nonnormally distributed data. Comparison of these variables was performed with the Kruskall-Wallis or Mann-Whitney U tests.
Qualitative variables are presented as the percentage of positive results found in the study, and the association between these variables and the studied factors was evaluated by Fisher's exact test. In all contrasts, a post hoc analysis correcting the level of statistical significance was performed by use of the Bonferroni test.
Factors related to renal function impairment were determined by including variables that were statistically significant in the univariate analysis into a stepwise logistic regression model with adjustment for type of transplantation and immunosuppressive agents.
All P values were based on a 2-tailed test of significance ( ). Statistical analysis was performed with SPSS, version P ! .05 11.0 (SPSS).
RESULTS
Overall, 156 nonselected recipients of a SOT who were admitted to the hospital were included in the study: 49 received a kidney transplant, 43 received a heart transplant, and 64 received a liver transplant. The main demographic and clinical characteristics of these patients are shown in table 1. Patient age was years; 65% of the patients were male, and mycophen-52 ‫ע‬ 12 olate acid and tacrolimus were the most commonly used immunosuppressive agents. The samples were obtained a median of 559 days (1-9481 days) after transplantation. Renal dysfunction (defined as a creatinine level of 11.5 mg/dL) was pre- BK viruria and viremia. Among our 156 patients, we found BKV viruria in 29 (19%) and viremia in 9 (6%). Both viruria and viremia were significantly more common among recipients of kidney (26.5% and 12.2%, respectively) and heart transplants (25.5% and 7%, respectively) than among recipients of liver transplants (7.8% and 0%, respectively) (table 2).
Correlation of BKV viremia and clinical data. The main characteristics of the 9 viremic patients (6 recipients of kidney transplants and 3 recipients of heart transplants) are summarized in table 3. Viremia was detected 162 days (3-3749 days) after transplantation (a median of 52 days after kidney transplantation and 1257 after heart transplantation). In patients 3-5, viremia was detected immediately after transplantation. All but 1 of the viremic patients had simultaneous viruria [10] .
All viremic recipients of kidney transplants and 1 recipient of a heart transplant had elevated levels of serum creatinine at the time viremia was detected (table 3). The latter patient had another potential cause of renal function impairment (obstructive renal disease after therapy with sulphonamides prescribed for nocardiosis). Two of the viremic recipients of renal transplants (patients 1 and 2) developed permanent renal function damage. Both patients had received a second transplant after loss of their first transplanted kidneys because of BKV infection (10 and 5 years earlier, respectively), which also reinfected the second allograft soon after transplantation. Unfortunately, the viruria and viremia status of these patients at the time they received a second transplant is unknown. Finally, we investigated the potential relationship between BKV replication and renal function in our SOT population. Creatinine levels for patients without BKV, patients with BKV viruria, and patients with BKV viremia were 1.3 mg/dL (0.5-14.3 mg/dL), 1.9 mg/dL (1.1-8.9 mg/dL), and 3.5 mg/dL (0.8-9.5 mg/dL), respectively (table 4) . When analyzed by type of SOT, we found a significant impact of BKV replication in the renal function for recipients of heart transplants but not for recipients of liver or kidney transplants (table 4) .
Independent factors related to impaired renal function were renal transplantation (OR, 13.3); BKV replication, including viruria or viremia (OR, 3.4); and mycophenolate use (OR, 3.5) (table 5).
DISCUSSION
Our point prevalence study shows BKV replication in kidney, heart, and liver transplant recipients and its association with poor renal function. In patients with kidney transplantation, viruria has been described in 13.5%-68% [11] [12] [13] , which is similar to the 25% prevalence found in our study. The clinical significance of BKV viruria and viremia in nonrenal SOT is almost unknown. The 25% prevalence of BKV viruria among recipients of heart transplants was quite a surprise. In 2 series of heart transplant recipients, which included 32 and 45 patients, the prevalence of BKV viruria was 25% and 46%, as determined by PCR [5, 6] . Among recipients of liver transplants, the rate of viruria was 8% in our series, 6.2% in the series of Splendiani et al. [11] , and 8% in the series of Marshall et al. [14] . BKV viruria has also been described in recipients of bone marrow transplants [15] and after pancreas transplantation (6%-11%) [16, 17] .
Although we found patients with viruria and viremia among our patients who received heart or liver transplants, we were not able to find any disease clearly attributable to BKV. For recipients of nonrenal SOT and hematopoietic stem cell transplants, chronic renal dysfunction is usually attributed to calcineurin inhibitor toxicity, but polyomavirus nephropathy has been described after heart [6, 18, 19] , lung, and pancreas transplantation and in recipients of stem cell transplants [3] .
Average time of diagnosis of BKV disease is between 7 and 12 months. It is of interest that, in our series, 4 patients had an episode of viremia immediate after transplantation. When further analyzed, we found that these patients received their allograft after a short period of dialysis and that all of them had residual diuresis from their own kidneys. Therefore, the virus could have already been present in their native kidneys, or it may have come from the donor. None of these patients developed permanent renal impairment, although this was present when plasma and urine samples were obtained.
We found higher creatinine levels in viruric and viremic patients, and BKV replication was found to be an independent factor related to renal dysfunction in our series. Although the elevated creatinine levels could also have been related to other conditions, the association between the presence of viral DNA in blood and impairment of renal function has been also described by other authors [20, 21] . The role of mycophenolate as independent predictor of renal impairment in our study population is not clear. It may reflect differences in the use of mycophenolate for different types of transplantation (e.g., use of this drug is less common in liver transplantation) or even its use in patients with higher risk of renal function impairment. In recipients of renal transplants, some authors have found a significant relationship between the use of tacrolimus with mycophenolate and BKV viremia or viruria [13] . However, in our study, the combination was not associated with renal dysfunction or with BKV replication in any type of transplant (table 4) .
When analyzed separately in each type of SOT, we found a significant impact of BKV replication on the renal function of recipients of heart transplants but not of recipients of liver transplants, who seem to have a lower risk of BKV disease (table 4) . We could not demonstrate either an independent impact of BKV replication on the renal function of our patients who received kidney transplants, probably because samples were mostly obtained soon after transplantation (median, 31 days after transplantation), and at this early stage, renal dysfunction is multifactorial and far too common (84% of kidney transplant recipients). In the study by Brennan et al. [13] , the median times of onset of viruria and viremia were 40 and 60 days after kidney transplantation, respectively.
Limitations of our study include the absence of follow-up sampling of patients with BKV viruria (because this was a prevalence study), the unavailability of renal biopsy specimens, and the fact that quantitative PCR was not performed. In addition, the different schedule of operative revisions in each transplant program may have resulted in a selection bias in the submission of samples to the laboratory that could have caused us to overestimate the real prevalence and to prevent detection of earlier or later reactivation of infection. Finally, with this pilot study, we cannot elucidate whether immunosuppression should be decreased in a recipient of a nonrenal transplant with BKV detected in blood and/or urine. More data obtained during an incidence study are clearly needed.
In summary, BKV replication is prevalent among adult recipients of nonrenal SOTs. BKV replication is a significant predictor of a poor renal function, and its early detection should now be actively and regularly pursued in this era of new therapeutic strategies.
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